Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

March 14, 2013

Las Vegas, Nevada

Continuing Medical Education

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum 3.5 of AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

This online educational activity is specifically designed for community oncologists, hematologists, and other health-care professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians' assistants, etc.) involved and/or interested in the therapeutic management of patients with hematologic malignancies.

Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize new insights into the biology of hematologic malignancies, and explain how these findings are being used to develop new and improved treatment strategies
  • Review the latest clinical trial updates on new and emerging therapies for hematologic malignancies, and discuss practical issues in incorporating these agents into clinical practice
  • Incorporate novel tools and strategies for diagnosis, prognosis, and risk stratification into management of hematologic malignancies
  • Consider various patient subgroups (younger, elderly, newly diagnosed, relapsed, treatment-refractory, etc.) when formulating treatment algorithms for patients with hematologic malignancies
  • Discuss major findings and expert perspectives presented at ASH 2012 and their potential impact on current clinical guidelines and best practices